



(51) International Patent Classification:

C07J 63/00 (2006.01) *A61K 31/18* (2006.01)
A61K 31/56 (2006.01)

(21) International Application Number:

PCT/US2014/014647

(22) International Filing Date:

4 February 2014 (04.02.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/761,403 6 February 2013 (06.02.2013) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).(72) Inventors: SWIDORSKI, Jacob; c/o Bristol-Myers
Squibb Company, 5 Research Parkway, Wallingford, Con-
necticut 06492 (US). VENABLES, Brian, Lee; c/o Bris-
tol-Myers Squibb Company, 5 Research Parkway, Walling-
ford, Connecticut 06492 (US). LIU, Zheng; c/o Bris-
tol-Myers Squibb Company, 5 Research Parkway, Walling-
ford, Connecticut 06492 (US). SIN, Ny; c/o Bristol-Myers
Squibb Company, 5 Research Parkway, Wallingford, Con-
necticut 06492 (US). MEANWELL, Nicholas, A.; c/o
Bristol-Myers Squibb Company, 5 Research Parkway,

Wallingford, Connecticut 06492 (US). **REGUEIRO-REN,
Alicia**; c/o Bristol-Myers Squibb Company, 5 Research
Parkway, Wallingford, Connecticut 06492 (US).


(74) Agents: LEVIS, John, F. et al.; Bristol-Myers Squibb
Company, Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.


(84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: C-19 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY



(I)



(II)

(57) **Abstract:** Compounds having drug and bio-affecting
properties, their pharmaceutical compositions and methods of
use are set forth. In particular, C-19 modified triterpen-
oids that possess unique antiviral activity are provided as
HIV maturation inhibitors, as represented by compounds of
Formulas (I) and (II), wherein R1 is as defined herein and
does not represent either an isopropyl or isopropenyl
group: (Formula (I)) and (Formula (II)). These compounds
are useful for the treatment of HIV and AIDS.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*